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Introduction: Although radiation therapy (RT) is an effective treatment for malignant atelectasis,
its accurate delivery is challenging because of difﬁculty differentiating between tumor and ate-
lectatic lung. Furthermore, reexpansion of lung during treatment repositions tumor and normal
structures necessitating replanning to ensure treatment accuracy. Facilitating lung reexpansion
before initiation of RT may improve RT treatment accuracy, spare normal tissue, and reduce
obstructive symptoms. We report a case of reexpansion of right upper lobe (RUL) atelectasis
caused by use of continuous positive airway pressure (CPAP) before RT.
Case report: A 52-year-old woman presented with dyspnea and cough. Imaging studies showed an
RUL mass with atelectasis. Bronchoscopy showed extrinsic compression of the RUL and middle
lobe bronchi. Biopsy showed small cell lung cancer. Staging with positron emission tomography-
computed tomography (CT) and contrast enhanced CT of brain showed no other disease.
Following 4 cycles of platinum-based chemotherapy, CT imaging showed a decrease in tumor
volume, but persistent RUL atelectasis. She agreed to participate in an institutional study to
evaluate the use of CPAP to reduce respiratory motion and immobilize tumors during RT. During
CPAP training, she complained of vertigo, headache, and weakness and refused simulation. The
next day she reported less dyspnea and completed training and CT simulation without difﬁculty.
CT simulation with CPAP showed reexpansion of the RUL. Lung volume increased from 2170 to
3767 mL (74 %). Gross tumor volume, clinical volume, and planning volume decreased 46%, 45%,
and 38%, respectively. Mean lung dose and mean heart dose decreased 20% and 51%, respectively.Sources of support: Supported by unrestricted grants from the LeRoy Schecter Foundation and Parasol Foundation.
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RUL remained inﬂated throughout treatment.
Conclusion: This is the ﬁrst reported use of CPAP for reexpansion of atelectasis before RT
planning and treatment. Reexpansion of atelectasis improved RT planning, decreased dose to
uninvolved lung, and removed the need for replanning. Further study of CPAP as an initial
intervention to improve RT delivery in patients with malignant atelectasis is warranted.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Atelectasis from endobronchial obstruction or external
bronchial compression may cause respiratory distress and
obstructive pneumonia.1,2 Rapid initiation of treatment is
important to open the obstruction and relieve symptoms.
Endobronchial lesions respond well to treatment with
invasive bronchoscopic techniques such as laser ablation,
cryotherapy, and stent placement and, if treated early,
patients will often experience rapid lung reexpansion.3,4
When atelectasis is from external bronchial compres-
sion or if invasive bronchoscopic techniques are unavai-
lable, obstructing tumors are often treated with radiation
therapy (RT). Accurate placement of radiation ﬁelds is
challenging because of difﬁculty in differentiating
between tumor and atelectatic lung on computed tomog-
raphy (CT) images alone.5 In addition, lung reexpansionFigure 1 (A, B) Diagnostic positron emission tomography comduring the course of treatment may shift the location of
the tumor and normal structures away from their original
positions. Replanning of the radiation ﬁelds to account for
changing organ position resulting from lung reexpansion
is essential to ensure treatment accuracy. We hypothe-
sized that facilitating lung reexpansion before initiation of
RT would improve treatment accuracy and reduce the
need for replanning radiation treatments.
We report the occurrence of reexpansion of right upper
lobe (RUL) atelectasis in a patient with small cell lung
cancer caused by use of continuous positive airway
pressure (CPAP) during RT treatment planning.
Case presentation
A 52-year-old woman with a 60 pack-year history of
smoking and a history of ischemic heart disease presentedputed tomography scan before initiation of chemotherapy.
Figure 2 (A) Planning computed tomography (CT) scan without continuous positive airway pressure (CPAP). (B) Planning CT scan
with CPAP.
Table 1 Size of planning structures and dose to normal
organs with and without CPAP
Parameters FB CPAP D %
GTV (mL) 388 209 179 46
CTV (mL) 605 331 275 45
PTV (mL) 902 560 342 38
Lung volume (mL) 2170 3767 1597 þ74
Mean lung dose (Gy) 20.5 16.3 4 20
V5 (%) 51.8 43.9 8 15
V20 (%) 34.8 27.4 7 21
Heart volume (mL) 510 515 5 þ1
Mean heart dose (Gy) 16.4 8.0 8 51
V10 (%) 37.7 21.0 17 44
V20 (%) 28.3 10.6 18 62
V30 (%) 21.5 7.1 14 67
Mean spine dose (Gy) 18.5 12.7 6 31
Mean esophagus
dose (Gy)
37.7 31.1 7 17
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breath. Chest x- ray and CT scans showed an RUL mass,
atelectasis, mediastinal widening, and a right-sided
pleural effusion. Positron emission tomography (PET)-
CT scan (Fig 1A,B) showed disease limited to the thorax.
Contrast enhanced CT of the brain was normal. Bron-
choscopy showed extrinsic compression and inﬁltration of
the RUL and the right middle lobe bronchi. Broncho-
scopic biopsy showed small cell lung cancer. Thoracent-
esis showed no malignant cells in pleural ﬂuid. Systemic
treatment was initiated with cis-platinum and etoposide.
She developed acute renal failure after 2 cycles. After
recovery, 2 cycles of carbo-platinum and etoposide were
given.
The patient was referred for outpatient RT. She com-
plained of persistent cough and dyspnea on exertion. She
continued to smoke. Physical examination showed a thin
woman in no respiratory distress. Vital signs were normal.
Breath sounds were absent in the right upper and mid-
chest. The liver and spleen were not palpable. The
extremities were without edema. The prescribed dose was
60 Gy speciﬁed as 95% dose to 95% of the planning
target volume. The initial planning CT (Fig 2A) showed
partial reduction in the RUL mass and persistent RUL
atelectasis. The total lung volume was 2170 mL. Mean
lung dose (MLD), V5, and V20 were 20.5 Gy, 51.8%, and
34.8%, respectively. The patient was offered participation
on an Institutional Ethics Committeeeapproved trial to
evaluate CPAP for improving RT delivery by reducing
respiratory motion. Resolution of atelectasis was not an
indication for participation. After obtaining informed
consent, CPAP training began within the RT department
before CT simulation by administering CPAP for 1 hour
at 15 cm H2O.
6 After 30 minutes, she complained of
vertigo, headache, and weakness and refused further
training or CT simulation. The next day, she reported less
dyspnea. She returned in 1 week and completed CPAP
training and CT simulation without difﬁculty. CT simu-
lation with CPAP (Fig 2B) showed reexpansion of theRUL. Table 1 shows that with use of CPAP total lung
volume increased 74% to 3,767 mL, GTV, CTV and
planning target volume decreased 46%, 45%, and 38%,
respectively. Figure 3 shows a dose-volume histogram
comparing dose with tumor and normal structures with
and without CPAP. MLD and mean heart dose decreased
20% and 51%, respectively.
CPAP was used daily with the same technique as used
during simulation: for 1 hour before and during treatment.
Figure 4 shows a cone beam CT image from day 11
demonstrating that the RUL remained inﬂated throughout
treatment.
After the 11th treatment, the patient began complain-
ing of headaches, weakness, and confusion. A magnetic
resonance imaging scan of the brain suggested lep-
tomeningeal disease. Chest RT was discontinued, and RT
to the cranial contents were started. She died 8 weeks
posttreatment.
Figure 3 Dose volume histogram showing doses with and without continuous positive airway pressure.
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To the best of our knowledge, this is the ﬁrst reported
case describing use of CPAP for reexpansion of obstructive
atelectasis from malignancy before RT. CPAP has been
long used as a treatment for sleep apnea and more recently
as a prophylactic therapy and treatment for postoperative
atelectasis.7 In this case, the intent of CPAP was to reduce
respiratory motion and preserve normal lung function.
Reexpansion of the RUL atelectasis was an unexpected
beneﬁt that persisted throughout the course of RT.
When atelectasis is present, functional imaging studies
such as PET-CT provide improved discrimination between
collapsed lung and tumor and are useful for planning RT.8
However, use of PET-CT in treatment planning is often
limited because studies obtained before developing atel-
ectasis may not provide an accurate representation of the
tumor location once atelectasis occurs. Scans obtained
when atelectasis is present may lose usefulness as the ate-
lectatic lung reexpands. Furthermore, there may be insuf-
ﬁcient time to obtain PET-CT imaging before initiating RT
in patients who present with rapid onset of symptoms.5Figure 4 Cone beam computed tomography scan showingRecently, our group reported reduced tumor motion
and expanded lung volumes in patients who received
stereotactic body RT with CPAP.6 The improvements
observed in this case were largely consistent with our
earlier ﬁndings, which showed an increase in total lung
volume and decrease in dose to the lung and heart.6
Although CPAP had no effect on GTV in our earlier
study, in this case report, GTV was reduced by 46%
because of reexpansion of the lung and improved identi-
ﬁcation of tumor for contouring.6 The decreases in lung
V5, V20, and MLD with CPAP were less than expected
because some of the reexpanded lung was irradiated. The
decrease in heart dose was substantial because depression
of the diaphragm repositioned the heart out of the path of
the radiation beam.
Reexpansion of atelectasis with chemotherapy alone is
uncommon and lung reexpansion often occurs only after
RT is added to the therapeutic plan.9 In this case, the
reduction in tumor volume from the ﬁrst 4 cycles of
chemotherapy contributed to the rapid lung reexpansion
and resolution of atelectasis caused by the use of CPAP.
Because this patient received no additional chemotherapypersistent lung expansion during course of treatment.
140 S. Appel et al Advances in Radiation Oncology: AprileJune 2016between simulations, the vertigo, headaches, and weak-
ness the patient described during the ﬁrst use of CPAP
may have been caused by lung reexpansion. However, use
of CPAP may also have caused a transient early occur-
rence of symptoms from the leptomeningeal disease that
presented soon after starting RT. However, the absence of
symptom recurrence during subsequent CPAP use sug-
gests that these initial symptoms were due to lung reex-
pansion rather than leptomeningeal tumor.
Because a 4-dimensional scan was not obtained during
the initial simulation, we were unable to fully assess the
reduction in respiratory motion caused by use of CPAP. A
4-dimensional scan was obtained during the simulation
with CPAP and showed negligible tumor motion and was
not used for planning. Because our experience with CPAP
is limited, we are unable to offer guidelines for selection
of patients with atelectasis most likely to beneﬁt from
treatment with CPAP. Also, we do not know if longer
duration or repeated use of CPAP may prove to be
effective in patients who are refractory to initial use of
CPAP treatment. The use of CPAP to facilitate reexpan-
sion of atelectasis does not replace other available thera-
peutic options. Instead, CPAP is an additional therapeutic
option to consider that may facilitate lung reexpansion
before initiation of RT. Further study is suggested to
better deﬁne appropriate patient selection and optimize
the use of this technique.
Conclusion
The use of CPAP caused reexpansion of atelectasis
resulting from malignant bronchial obstruction. Lung
reexpansion improved treatment planning by allowing for
better identiﬁcation and targeting of the obstructing
lesion, sparing of normal lung tissue from radiationexposure, and reducing the need for replanning treatment.
Further study to assess the use of CPAP for reexpansion
of atelectasis resulting from malignant bronchial
obstruction is indicated.References
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